Studies with CUTO64, derived at time of entrectinib progression, suggests the tumor remained partially dependent on ROS1 as maximal reduction in cell viability was achieved when ROS1 inhibition was paired with MAPK pathway inhibition. This evidence concerns the gene ROS1 and neoplasm.